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Abstract
In a phase III, double-blind, randomized study, treatment with ruxolitinib resulted in signiﬁcant reductions in
splenomegaly and symptom burden in patients with intermediate-2 or high-risk myeloﬁbrosis and was asso-
ciated with a survival advantage relative to placebo. In this post hoc analysis, we assessed the effect of rux-
olitinib treatment on measures of metabolic and nutritional status.
Background: In the COMFORT (COntrolled MyeloFibrosis Study with ORal JAK Inhibitor Therapy)-I study, the Janus
kinase (JAK)1/JAK2 inhibitor ruxolitinib provided signiﬁcant reductions in splenomegaly, improvements in myeloﬁ-
brosis (MF)-related symptoms, and a survival advantage relative to placebo in patients with intermediate-2 or high-risk
MF. In this post hoc analysis, we assessed the effects of ruxolitinib treatment on measures of metabolic and nutritional
status. Patients and Methods: Patients were randomized to receive ruxolitinib (n ¼ 155; 15 or 20 mg twice a day for
patients with baseline platelet counts of 100-200  109/L or > 200  109/L, respectively) or placebo (n ¼ 154). The
primary end point was the proportion of patients with a  35% spleen volume reduction from baseline to week 24. A
secondary end point was the proportion of patients with  50% improvement in Total Symptom Score (TSS) from
baseline to week 24, measured using the modiﬁed Myeloﬁbrosis Symptom Assessment Form version 2.0. Weight,
cholesterol, and albumin were measured at speciﬁed time points throughout the study. Results: Compared with
placebo, ruxolitinib treatment was associated with increased weight (mean change: 3.9 kg vs. 1.9 kg), total
cholesterol (mean percentage change: 26.4% vs. 3.3%), and albumin levels (mean percentage change: 5.8% vs.
1.7%) at week 24; sustained improvements were observed with longer-term ruxolitinib therapy. Relative to placebo,
increases in mean weight, total cholesterol, and albumin levels were observed with ruxolitinib treatment regardless of
the degree of spleen volume and TSS reductions at 24 weeks. Conclusion: Treatment with ruxolitinib improved
measures of metabolic and nutritional status of patients with intermediate-2 or high-risk MF.
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Myeloﬁbrosis (MF) is a chronic Philadelphia chromosome-
negative myeloproliferative neoplasm that primarily affects older
individuals1,2 and is characterized by progressive bone marrow
ﬁbrosis and ineffective hematopoiesis.3-5 Patients with MF typi-
cally experience cytopenias, splenomegaly—attributable toThis research was presented, in part, at the 54th American Society of Hematology
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debilitating symptoms, which might severely diminish their
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loss appear to be consequences of systemic inﬂammation
and hypercatabolism driven by abnormal levels of circulating
cytokines.9,10
Dysregulated signaling of the Janus kinase (JAK)esignal trans-
ducers and activators of transcription (STAT) pathway is central to
the pathogenesis of MF.11 Various mechanisms of this dysregulated
signaling have been identiﬁed, including somatic mutations that
result in neoplastic myeloproliferation and dysfunctional hemato-
poiesis.11-13 In addition, aberrant JAK-STAT signaling underlies
secondary effects of myeloproliferation, particularly the excess
proinﬂammatory cytokine production responsible for MF-associated
symptoms and metabolic disturbances and chronic weight loss.9,10
Cachexia is a multifactorial syndrome characterized by the loss of
skeletal muscle and fat mass with detrimental consequences on
quality of life, morbidity, and mortality in patients with MF.7 The
causative factors underlying cachexia in MF are complex and not
well understood, but they might include reduced nutritional intake
due to massive splenomegaly and metabolic disturbances caused by
the systemic inﬂammatory state. The JAK-STAT pathway is a key
regulator of proinﬂammatory cytokines such as interleukin (IL)-6
and tumor necrosis factor (TNF)-a, which have been implicated in
the modulation of body mass and cachexia.14,15 In addition, C-
reactive protein (CRP), a marker of systemic inﬂammation, is
increased in patients with cancer-related cachexia.14 Moreover,
abnormal levels of proinﬂammatory cytokines have been identiﬁed
as negative prognostic factors for overall survival in patients with
primary MF, along with cachexia and constitutional symp-
toms.1,9,16 In addition to weight loss, cachexia is often associated
with hypoalbuminemia.17 A chronic inﬂammatory and hyper-
catabolic state has been shown to inhibit albumin synthesis in the
liver, further contributing to cachexia-induced hypoalbuminemia.18
Myeloﬁbrosis is also characterized by abnormally low cholesterol
levels, which has been associated with shortened survival.7,19,20 An
analysis of lipid data from 207 patients with MF treated at a single
center showed that decreased levels of total or high-density lipo-
protein cholesterol (HDL-C) were associated with shortened sur-
vival independent of the Dynamic International Prognostic Scoring
System-Plus.20
Treatment with ruxolitinib, an oral JAK1/JAK2 inhibitor,
resulted in signiﬁcant reductions in spleen volume and improve-
ments in symptoms and quality of life in patients with intermediate-
2 or high-risk MF in 2 phase III studies, COMFORT (COntrolled
MyeloFibrosis Study with ORal JAK Inhibitor Therapy)-I21 and
COMFORT-II.22 In addition, evidence from both trials suggested
that ruxolitinib was associated with a survival advantage compared
with placebo21,23 and what was previously considered best available
therapy.24 Ruxolitinib treatment has been shown to modify plasma
markers associated with MF symptomatology.21 For example, in the
COMFORT-I study, ruxolitinib-treated patients had decreased
plasma levels of inﬂammatory markers commonly upregulated in
MF such as TNF-a, IL-6, and CRP.21
We hypothesized that the clinical beneﬁt of ruxolitinib might be
related at least in part to the alleviation of cachexia and improvement
of patients’ metabolic/nutritional status because ruxolitinib-treated
patients in COMFORT-I generally experienced an increase in
body weight whereas placebo-treated patients experienced a decrease
in weight. Therefore, we conducted a post hoc analysis of long-termdata from the COMFORT-I study to further investigate the effects
of ruxolitinib treatment on body weight, total cholesterol, and al-
bumin, and the association of these changes with a reduction in
spleen volume and MF-related symptoms.
Patients and Methods
Patients and Study Design
Detailed methods for the COMFORT-I study have been previ-
ously reported.21 Brieﬂy, eligible patients from the United States,
Canada, or Australia were  18 years of age with primary MF,
post-polycythemia vera MF, or post-essential thrombocythemia MF;
disease that was classiﬁed as intermediate-2 or high-risk according
to the International Prognostic Scoring System; a platelet count
of  100  109/L; and a palpable spleen ( 5 cm below the left
costal margin). All patients had disease requiring treatment and were
refractory to or intolerant of available therapies.
Eligible patients were randomized to receive placebo (n ¼ 154) or
ruxolitinib (n ¼ 155) at 2 different starting dosages depending on
baseline platelet count. Patients with a platelet count of 100 to
200  109/L received a 15-mg twice-a-day (b.i.d.) starting dosage of
ruxolitinib, and those with a platelet count > 200  109/L received
a 20-mg b.i.d. starting dosage of ruxolitinib; dosages were adjusted
for lack of efﬁcacy or excess toxicity. Patients randomized to placebo
crossed over to ruxolitinib or discontinued within 3 months of the
primary data analysis (when all patients completed 24 weeks and half
of the patients remaining in the study completed 36 weeks of
treatment). The primary end point was the proportion of patients
achieving  35% reduction in spleen volume (assessed using
abdominal imaging) from baseline to week 24. A secondary end
point was the proportion of patients who achieved  50% reduction
in Total Symptom Score (TSS) from baseline to week 24 using the
modiﬁed Myeloﬁbrosis Symptom Assessment Form version 2.0.21
The study was conducted in accordance with the International
Conference on Harmonization guidelines for Good Clinical Practice.
The protocol was approved by the institutional review board at
each participating site, and all patients provided written informed
consent.
Evaluations
All patients originally randomized to ruxolitinib or placebo were
included in this post hoc analysis. For patients in the placebo group
who crossed over to ruxolitinib, data were only included for time
points before crossover. Body weight was measured as part of the
routine assessment of patients during study visits at baseline, weeks
4, 8, 12, 16, 24, 36, and every 12 weeks thereafter. The plasma lipid
proﬁle was assessed at baseline, weeks 4, 12, 24, 48, and every 24
weeks thereafter. Serum albumin levels were assessed at baseline,
weeks 2, 4, 6, 8, 12, 16, 20, 24, and every 6 weeks thereafter. For
patients who received placebo, these parameters were assessed up to
week 48, because most patients who received placebo either dis-
continued participation in the study or crossed over to ruxolitinib
by this time point. All patients were instructed to fast for at least 8
hours before each study visit. Lipid and albumin concentrations
were assessed at a central laboratory. Spleen volume was assessed
using magnetic resonance imaging or computed tomography at
baseline and every 12 weeks thereafter. The TSS was assessed daily
using electronic diaries through week 24.Clinical Lymphoma, Myeloma & Leukemia April 2015 - 215
Table 1 Baseline Body Weight, Body Mass Index, Total
Cholesterol, and Albumin
Characteristic
Ruxolitinib
(n [ 155)
Placebo
(n [ 154)
Mean Body Weight (SD), kg 72.2 (16.2) 72.2 (13.7)
Mean BMI (SD) 25.1 (5.0) 24.8 (4.0)
BMI <22, % of Patients 23 28
Mean Total Cholesterol (SD), mg/dL 117.3 (34.5) 114.3 (35.6)
Total Cholesterol <150 mg/dL, % of
Patients
82 82
Mean LDL-C (SD), mg/dL 55.4 (26.2) 53.8 (26.5)
Mean HDL-C (SD), mg/dL 29.3 (10.9) 29.1 (10.7)
Mean Albumin (SD), g/L 42.8 (3.7) 41.8 (4.1)
There were no signiﬁcant differences in baseline characteristics between treatment groups with
the exception of albumin (P < .05). P values were calculated using the t test for continuous
variables and the c2 test for categorical variables.
Abbreviations: BMI ¼ body mass index; HDL-C ¼ high-density lipoprotein cholesterol; LDL-C ¼
low-density lipoprotein cholesterol.
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216 -Statistical Analyses
Body weight, cholesterol, and albumin parameters at baseline
were compared between treatment groups using the t test for
continuous variables and the c2 test for categorical variables.
Changes from baseline to week 24 in body weight, total cholesterol,
and albumin were compared between treatment groups using the t
test. Additionally, ruxolitinib-treated patients were stratiﬁed ac-
cording to spleen volume reduction status at week 24 ( 35%, 10%
to < 35%, < 10% reduction from baseline) and the change from
baseline to week 24 in body weight, cholesterol, and albumin were
compared with all patients who received placebo using analysis of
variance. A similar analysis was conducted stratifying ruxolitinib-
treated patients according to TSS status at week 24 ( 50% or <
50% reduction in TSS from baseline at week 24). All P values re-
ported are descriptive and not intended for statistical inferences.
For the purpose of these analyses, upper limits for total choles-
terol and low-density lipoprotein cholesterol (LDL-C) were deﬁned
according to the National Cholesterol Education Program Adult
Treatment Panel III guidelines for adults without cardiovascular
risk (the active guidelines at the time of initiation of COMFORT-I)
as 240 mg/dL and 160 mg/dL, respectively; the lower limit for
HDL-C was deﬁned as 40 mg/dL.25 In the absence of ofﬁcial
guidelines deﬁning a lower limit for total cholesterol, 150 mg/dL
was used, which is consistent with data that suggest that total
cholesterol < 150 mg/dL is associated with poorer prognosis in
patients with MF.7Plasma Marker Analysis
Plasma samples were collected at baseline and week 24 from
placebo- and ruxolitinib-treated patients, and levels of a broad panel
of plasma markers were determined using the Myriad RBM Human
Multi-Analyte Proﬁling panel. These data, along with levels of total
cholesterol, body weight, and albumin at baseline and week 24,
were imported into OmicSoft Array Studio version 6.0 for analysis.
Patients lacking both baseline and week 24 measurements for total
cholesterol, body weight, and albumin were excluded. Changes at
week 24 relative to baseline were determined and converted to
LOG2 scale, with heat maps generated using hierarchical clustering.
Because of differences in the magnitude of the changes in plasma
proteins relative to weight change, heat maps colors were normal-
ized using Robust Center Scaling (OmicSoft Array Studio version
6.0), which subtracts the median value and then centers the result
by dividing it by the median absolute deviation.
Results
Baseline demographic and disease characteristics were generally
similar between ruxolitinib and placebo groups.21 Patients in the
ruxolitinib and the placebo groups had similar baseline values for
body weight and lipid levels, and the mean albumin level was higher
in the ruxolitinib group (Table 1).
Treatment Effects on Body Weight, Total Cholesterol, and
Albumin Levels
Patients who received ruxolitinib experienced gradual increases in
body weight, whereas patients who received placebo experienced
decreases in body weight over time (Figure 1A). At week 24, theClinical Lymphoma, Myeloma & Leukemia April 2015mean weight increase was 3.9 kg in the ruxolitinib group, and a
mean weight decrease of 1.9 kg was observed in the placebo group
(P < .0001). Weight appeared to plateau at approximately 36 weeks
in the ruxolitinib group; the mean weight increase from baseline in
ruxolitinib-treated patients was 5.7 kg at week 96. Overall, 149
ruxolitinib-treated patients (96.1%) experienced any weight increase
at some time during this study. Consistent with weight increase, the
mean body mass index of ruxolitinib-treated patients increased by
approximately 1.4 compared with a decrease of 0.7 in placebo-
treated patients at week 24 (P < .0001), and stabilized after
approximately 36 weeks of treatment.
As with body weight and body mass index, total cholesterol
increased in patients who received ruxolitinib and decreased in
patients who received placebo (Figure 1B). At week 24, the mean
percentage increase from baseline in total cholesterol among
ruxolitinib-treated patients was 26.4% (observed mean increase:
29.5 mg/dL) versus a mean decrease of 3.3% (observed mean
decrease: 4.98 mg/dL) in the placebo group (P < .0001). At 96
weeks, the mean percentage increase in total cholesterol among
ruxolitinib-treated patients was 35.8% (observed mean increase:
38.0 mg/dL). A total of 150 patients (96.8%) in the ruxolitinib
group experienced any degree of increase in total cholesterol. For
most of the ruxolitinib-treated patients, the levels of total cholesterol
and LDL-C did not exceed the upper limits deﬁned for this analysis
(240 mg/dL and 160 mg/dL, respectively; see Supplemental
Figure 1A and B in the online version). Median total cholesterol
levels of approximately 150 mg/dL and median HDL-C levels of
approximately 40 mg/dL were achieved by week 4 and maintained
with long-term therapy (see Supplemental Figure 1A and C in the
online version).
Albumin levels increased in response to ruxolitinib treatment
(Figure 1C). After 24 weeks of treatment, ruxolitinib-treated pa-
tients experienced a mean increase in albumin levels of 5.8%
(observed mean increase: 2.3 g/L) compared with a mean decrease
of 1.7% (observed mean decrease: 0.8 g/L) in the placebo arm (P <
.0001). In the ruxolitinib group, albumin increases stabilized at
approximately 10 weeks and were maintained throughout the
study. At 96 weeks, the mean percentage increase in albumin
Figure 1 Mean Change in (A) Body Weight, (B) Total Cholesterol, and (C) Albumin Over Time in Patients Who Received Ruxolitinib or
Placebo. Vertical Lines Indicate the Standard Error of the Mean
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218 -among ruxolitinib-treated patients was 7.6% (observed mean in-
crease: 3.1 g/L). Overall, 147 ruxolitinib-treated patients (94.8%)
experienced any increase in albumin levels during the course of
the study.
Association of Increases in Body Weight, Total Cholesterol,
and Albumin With Spleen Volume Reduction
Analysis of weight change stratiﬁed according to the degree of
spleen volume reduction from baseline at week 24 showed that
relative to placebo, ruxolitinib-treated patients experienced weight
increases regardless of the degree of spleen volume reduction.
Ruxolitinib-treated patients with a spleen volume reduction of
 35% experienced a greater mean percentage increase in body
weight (7.5%) compared with patients with a spleen volume
reduction of 10% to < 35% (5.0% increase) and < 10% (2.5%
increase). In patients who received placebo, a 2.3% decrease in body
weight was observed (P < .001 for the 3 spleen volume reduction
group comparisons with placebo). This pattern was maintained
beyond week 24, and a greater reduction in spleen volume in
ruxolitinib-treated patients continued to be associated with greater
weight increase up to week 96 (Figure 2).
Similarly, analysis of changes in total cholesterol levels stratiﬁed
according to the degree of spleen volume reduction from baseline at
week 24 showed that compared with placebo, ruxolitinib treatment
was associated with increased total cholesterol levels regardless of the
degree of spleen volume reduction. The greatest reduction in spleen
volume ( 35%) at week 24 was associated with the highest mean
percentage increase in total cholesterol (41.6%) compared with
the increases in total cholesterol in patients with spleen volumeFigure 2 Mean Percentage Change From Baseline in Body Weight i
Reduction Group. Vertical Lines Indicate the Standard Erro
Clinical Lymphoma, Myeloma & Leukemia April 2015reductions of 10% to < 35% (17.0%) and < 10% (6.8%). In the
placebo group, a mean decrease in total cholesterol of 2.8% was
observed (P  .047 for the 3 spleen volume reduction group
comparisons with placebo).
Relative to placebo, improvements in serum albumin levels were
also observed in all ruxolitinib-treated patients regardless of the
degree of spleen volume reduction from baseline at week 24.
Ruxolitinib-treated patients with the largest degree of spleen volume
reduction ( 35%) at week 24 experienced the largest increase in
albumin levels from baseline (8.6%) compared with patients with a
spleen volume reduction of 10% to < 35% (5.6%) and < 10%
(1.0%). Patients randomized to placebo experienced a mean
decrease in albumin levels from baseline of 1.2% (P < .001 for
the  35% and 10% to < 35% spleen volume reduction group
comparisons to placebo; P ¼ .234 for the < 10% spleen volume
reduction group comparison with placebo).
Association of Increases in Body Weight, Total Cholesterol,
and Albumin With TSS
In the ruxolitinib arm, weight increase occurred regardless of
reduction in TSS at week 24. Patients with  50% reduction in
TSS had a mean weight increase of 6.3% and those with TSS
reduction < 50% had a mean weight increase of 5.3% at week 24.
In the placebo arm, patients experienced a 2.5% decrease in body
weight (P < .001 for both TSS reduction group comparisons with
placebo). With longer follow-up, weight continued to improve in
ruxolitinib-treated patients who had a  50% reduction in TSS,
with mean weight increase approximately 10% above baseline at
week 96 (Figure 3).n Ruxolitinib-Treated Patients by Week 24 Spleen Volume
r of the Mean
Figure 3 Mean Percentage Change From Baseline in Body Weight in Ruxolitinib-Treated Patients by Week 24 Total Symptom Score
Reduction Group. Vertical Lines Indicate the Standard Error of the Mean
Ruben A. Mesa et alThe mean percentage increase from baseline to week 24 in total
cholesterol was similar between the 2 TSS reduction groups (mean
percentage increases of 27.5% with TSS reduction  50% and
26.4% with TSS reduction < 50%). In the placebo group, a mean
decrease in total cholesterol levels of 3.5% was observed (P < .001
for both TSS reduction group comparisons with placebo).
In ruxolitinib-treated patients, changes in albumin levels
were slightly higher in patients who had a  50% reduction in
TSS (7.0%) at week 24 compared with patients with TSS
reduction < 50% (5.2%). Patients who received placebo experi-
enced a mean reduction in albumin levels of 1.6% (P < .001 for
both TSS reduction group comparisons with placebo).
Plasma Marker Expression
Hierarchical clustering analysis was used to compare changes in
body weight, total cholesterol, or albumin for each patient with
changes in a broad panel of plasma markers. Weight changes were
most closely associated with changes in leptin and erythropoietin,
total cholesterol changes were closely associated with changes in
leptin and alpha-fetoprotein, and albumin changes were most
closely associated with changes in insulin and leptin (Figure 4).
Discussion
The results of this post hoc analysis of the COMFORT-I study
showed that compared with placebo, ruxolitinib was associated with
clinically meaningful improvements in body weight, total choles-
terol, and serum albumin in patients with intermediate-2 or high-
risk MF. The weight increase associated with ruxolitinib therapy
had been previously reported in the phase I/II study of ruxolitinib in
MF and in the primary analyses of the phase III COMFORTstudies for a period up to 48 weeks12,21,22; however, this analysis
showed that the weight gain observed with ruxolitinib therapy in the
COMFORT-I study at the primary analysis was maintained with
long-term therapy. Gain in lean body mass in patients treated with
ruxolitinib in the COMFORT-I study might be even more sub-
stantive than that indicated by weight gain considering the decrease
in spleen mass and potential decrease in ﬂuid retention from edema.
Of note, the weight increase in ruxolitinib-treated patients was
accompanied by other metabolic improvements, indicative of the
overall improvement in the hypercatabolic state associated with MF.
Total cholesterol, which often decreases with MF, was low
(< 150 mg/dL) in approximately 80% of patients in the
COMFORT-I study at baseline. Although hypocholesterolemia has
been well documented in MF, typical total cholesterol levels in
patients with MF have not been extensively reported in the litera-
ture. Median total cholesterol values ranging from 132 mg/dL to
153 mg/dL in patients with primary MF have been reported pre-
viously,7,20 and these values are comparable with the baseline total
cholesterol values observed in the COMFORT-I cohorts. In this
analysis, ruxolitinib treatment was associated with increases in the
levels of total cholesterol, LDL-C, and HDL-C. These increased
levels were maintained with long-term therapy, and importantly, the
total cholesterol and LDL-C values in ruxolitinib-treated patients in
general did not exceed 240 mg/dL and 160 mg/dL, respectively,
indicating that ruxolitinib therapy did not increase the risk of
hypercholesterolemia.
Because hypocholesterolemia (total cholesterol < 150 mg/dL)
and weight loss have previously been associated with poorer prog-
nosis in patients with MF,7,19,20 the improvements in total
cholesterol and weight seen with ruxolitinib in the COMFORT-IClinical Lymphoma, Myeloma & Leukemia April 2015 - 219
Figure 4 Hierarchical Clustering of Plasma Markers With Changes in Weight Alone (Top), Changes in Total Cholesterol Alone (Middle),
or Changes in Albumin Alone (Bottom). Red Denotes Increases at Week 24 Relative to Baseline. Green Denotes Decreases at
Week 24 Relative to Baseline. Because of Differences in the Magnitude of Changes Between Markers, the Heat Map Color
Intensities Were Normalized
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220 -study might represent disease-modifying effects that contribute to
the prolonged survival advantage associated with ruxolitinib therapy
relative to placebo.23
Albumin is one of many parameters used to assess a patient’s
nutritional status. Low albumin levels have been shown to be a
predictor of morbidity and mortality in various disease states.26
Albumin synthesis has been shown to be decreased by proin-
ﬂammatory cytokines such as IL-6 and TNF-a.27 Proinﬂammatory
cytokines are thought to drive hypercatabolism in MF,28 and
increased expression levels of proinﬂammatory cytokines, particu-
larly IL-6 and TNF-a, and of markers of systemic inﬂammation
such as CRP,29 have been observed in patients with cancer-related
cachexia.15,30 In clinical trials, ruxolitinib treatment was associated
with reductions in the plasma levels of proinﬂammatory cytokines,
including IL-6 and TNF-a.12,21,22 In contrast, patients in the
placebo group of the COMFORT-I study maintained abnormally
high levels of these cytokines at week 24.21 Thus, reduction in levels
of proinﬂammatory cytokines with ruxolitinib treatment might be a
mechanism by which albumin levels increase in patients with MF.
Conclusion
Although the assessments of differences between treatment
groups in metabolic and nutritional parameters were only explor-
atory end points in this study, the considerable improvements inClinical Lymphoma, Myeloma & Leukemia April 2015body weight, cholesterol, and albumin seen in these post hoc ana-
lyses of COMFORT-I might help in the understanding of why
ruxolitinib was associated with an improvement in overall survival
relative to placebo in COMFORT-I or best available therapy in
COMFORT-II.23,24 Collectively, these results provide additional
evidence for the disease-modifying effects of ruxolitinib in patients
with MF.
Clinical Practice Points
 Cachexia is a common manifestation of MF and is a prognostic
indicator of poor survival.
 In 2 recent phase III studies, ruxolitinib treatment provided
signiﬁcant spleen volume reduction, improvement in MF-related
symptoms, and was associated with increased overall survival
compared with control patients.
 This post hoc analysis of the COMFORT-I study was conducted
to assess the effects of ruxolitinib treatment on measures of
metabolic and nutritional status.
 Compared with placebo, ruxolitinib treatment was associated
with increases in body weight, total cholesterol, and albumin
levels that were maintained with longer-term treatment.
 Ruxolitinib provided improvements in measures of metabolic
and nutritional status relative to placebo regardless of the degree
of reduction of splenomegaly or symptom burden.
Ruben A. Mesa et al This analysis showed that ruxolitinib treatment might ameliorate
the metabolic and nutritional abnormalities that are commonly
seen in patients with MF.Acknowledgments
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Supplemental Figure 1 Box and Whisker Plots of (A) Total Cholesterol, (B) LDL-C, and (C) HDL-C Levels Over Time in
Ruxolitinib-Treated Patients. The Solid Red Line Represents the Median
A
B
C
Abbreviations: HDL-C ¼ High-Density Lipoprotein Cholesterol; LDL-C ¼ Low-Density Lipoprotein Cholesterol.
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